Ticker League

Cash on Hand for Moderna (MRNA)

As of · Reported

Metric

Latest period

$5.21B

YoY change

-17.5%

5Y CAGR

+4.7%

Peak year (2021)

$10.73B

Cash on Hand history chart for Moderna (MRNA) from 2016 to 2025

Latest: $5.80B

Cash on Hand growth chart for Moderna (MRNA) from 2016 to 2025

Latest: -17.5%

Cash on Hand history table for Moderna (MRNA) from 2016 to 2025

  • 2025$5.80B-17.5%
  • 2024$7.03B-18.4%
  • 2023$8.60B-13.1%
  • 2022$9.90B-7.7%
  • 2021$10.73B+132.8%
  • 2020$4.61B+317.8%
  • 2019$1.10B-27.5%
  • 2018$1.52B+101.2%
  • 2017$756.03M-28.6%
  • 2016$1.06B—

Cash on Hand values are taken from Moderna's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Cash on Hand at Moderna (MRNA)

According to Moderna's latest reported financial statements, the company's latest reported cash and short-term investments is $5.21B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

2025's annual cash and short-term investments for Moderna (MRNA) came in at $5.80B – declined 17.5% year-over-year.

Moderna cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is +4.7%, with mixed annual results across the window.

Moderna cash and short-term investments plunged from $10.73B in 2021 to $5.80B in 2025, a 45.9% drawdown.

Across the available history, cash and short-term investments reached its high of $10.73B in 2021 and its low of $756.03M in 2017.

Moderna Cash on Hand by Year

Moderna Cash on Hand 2025: $5.80B

Moderna posted cash and short-term investments of $5.80B in 2025, declined 17.5% below 2024.

Moderna Cash on Hand 2024: $7.03B

In 2024, Moderna reported cash and short-term investments of $7.03B, declined 18.4% below 2023.

Moderna Cash on Hand 2023: $8.60B

Moderna cash and short-term investments in 2023 was $8.60B, declined 13.1% below 2022.

Moderna Cash on Hand 2022: $9.90B

2022's cash and short-term investments for Moderna came in at $9.90B, declined 7.7% below 2021.

Moderna Cash on Hand 2021: $10.73B

Moderna cash and short-term investments in 2021 was $10.73B.

See more financial history for Moderna (MRNA).

Sector peers by Cash on Hand

Healthcare peers of Moderna (MRNA), ranked by their latest cash and short-term investments

Frequently asked questions

Moderna (MRNA) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return